| Literature DB >> 35431714 |
Ehsan Nazarzadeh Zare1, Zari Fallah2, Van Thuan Le3,4, Van-Dat Doan5, Ackmez Mudhoo6, Sang-Woo Joo7, Yasser Vasseghian7, Mahmood Tajbakhsh2, Omid Moradi8, Mika Sillanpää9, Rajender S Varma10.
Abstract
The release of pharmaceuticals into the environment induces adverse effects on the metabolism of humans and other living species, calling for advanced remediation methods. Conventional removal methods are often non-selective and cause secondary contamination. These issues may be partly solved by the use of recently-developped adsorbents such as molecularly imprinted polymers. Here we review the synthesis and application of molecularly imprinted polymers for removing pharmaceuticals in water. Molecularly imprinted polymers are synthesized via several multiple-step polymerization methods. Molecularly imprinted polymers are potent adsorbents at the laboratory scale, yet their efficiency is limited by template leakage and polymer quality. Adsorption performance of multi-templated molecularly imprinted polymers depends on the design of wastewater treatment plants, pharmaceutical consumption patterns and the population serviced by these wastewater treatment plants.Entities:
Keywords: Contaminated water; Limitations; Molecularly imprinted materials; Pharmaceuticals; Remediation
Year: 2022 PMID: 35431714 PMCID: PMC8999999 DOI: 10.1007/s10311-022-01439-4
Source DB: PubMed Journal: Environ Chem Lett ISSN: 1610-3653 Impact factor: 13.615
Fig. 1Fabrication of molecularly imprinted polymers and their application in the remediation of pharmaceuticals from contaminated water. First, the polymerization is performed in the presence of the target drug. Then the drug template is formed after the drug is withdrawn by leaching operation. The size of the template depends on the size of the chemical structure of the drug
Common pharmaceuticals, their excretion mode, and therapeutic properties
| Pharmaceutical type | Emerging contaminants | Molecular formula | Molar mass (g mol−1) | Excretion | Therapeutic applications |
|---|---|---|---|---|---|
| Antibiotic | Amoxicillin | C16H19N3O5S | 365.40 | Urine | To treat bacterial infections |
| Antibiotic | Azithromycin | C38H76N2O14 | 748.99 | Urine | To treat some bacterial infections like middle ear infection, streptococcal sore throat, pneumonia, and diarrhea |
| Antibiotic | Cephalexin | C16H17N3O4S | 347.39 | Urine | To treat the infections of the respiratory, urinary, and genital tract |
| Antibiotic | Chlortetracycline | C22H23ClN2O8 | 478.88 | Urine | To treat the methicillin-resistant |
| Antibiotic | Clarithromycin | C38H69NO13 | 747.96 | Bile, Urine | To treat some bacterial infections like Helicobacter pylori, strep throat, bronchitis, and sinusitis |
| Antibiotic | Ciprofloxacin | C17H18FN3O3 | 331.34 | Bile, Urine | To treat some severe and complex infections |
| Antibiotic | Erythromycin | C36H65NO13 | 733.93 | Bile, Urine | To treat bacterial infections |
| Antibiotic | Gatifloxacin | C19H22FN3O4 | 375.39 | Urine | To treat eye infections |
| Antibiotic | Lincomycin | C18H35ClN2O6S | 406.54 | Bile, Urine | To treat the gram-positive microbes’ infections (respiratory tract and urinary tract infections, osteomyelitis, sepsis, otitis, and infectious arthritis) |
| Antibiotic | Metronidazole | C6H9N3O3 | 171.15 | Feces, Urine | To treat bacterial vaginosis and pelvic inflammatory disease |
| Antibiotic | Norfloxacin | C16H18FN3O3 | 319.33 | Bile, Urine | To treat gonorrhea and the infections of the urinary tract, bladder, and gynecological disease |
| Antibiotic | Ofloxacin | C18H20FN3O4 | 361.37 | Feces, Urine | To treat cellulite, pneumonia, urinary tract infections, and prostatitis |
| Antibiotic | Oxytetracycline | C22H24N2O9 | 460.43 | Urine | To treat the infection of the chest and mouth |
| Antibiotic | Penicillin | C16H18N2O4S | 334.40 | Bile, Urine | To treat infections |
| Antibiotic | Roxithromycin | C41H76N2O15 | 837.05 | Feces, Urine | To treat the infections of the respiratory, urinary tract, and soft tissues |
| Antibiotic | Sulfadiazine | C10H10N4O2S | 250.28 | Urine | To treat vaginal infections |
| Antibiotic | Sulfamethoxazole | C10H11N3O3S | 253.28 | Urine, Breast milk | To treat urinary tract infections, bronchitis, and prostatitis |
| Antibiotic | Tetracycline | C22H24N2O8 | 444.43 | Urine | To treat a wide variety of infections such as acne |
| Antibiotic | Trimethoprim | C14H18N4O3 | 290.32 | Urine | To treat urinary tract infections |
| Anticancer | Bleomycin | C55H84N17O21S3+ | 1415.55 | Urine | To treat cancer |
| Anticancer | Cyclophosphamide | C7H15Cl2N2O2P.H2O | 261.08 | Bile, Urine | To treat cancer |
| Anticancer | Docetaxel | C43H53NO14 | 807.88 | Urine | To treat cancer |
| Anticancer | Etoposide | C29H32O13 | 588.56 | Bile, Urine | To treat cancer |
| Anticancer | Epirubicin | C27H29NO11 | 543.50 | Bile, Urine | To treat cancer |
| Anticancer | 5-Fluorouracil | C4H3FN2O2 | 130.08 | Bile, Urine | To treat cancer |
| Anticancer | Ibrance (Palbociclib) | C24H29N7O2 | 447.54 | Feces, Urine | To treat the breast cancer |
| Anticancer | Methotrexate | C20H22N8O5 | 454.43 | Bile, Urine | To treat cancer |
| Anticancer | Oxaliplatin | C8H14N2O4Pt | 397.29 | Feces, Urine | To treat the colon cancer |
| Anticancer | Vincristine | C46H56N4O10 | 824.96 | Feces, Urine | To treat the lymphoblastic leukemia |
| Antidepressant | Amitriptyline | C20H23N | 277.40 | Urine | To treat the psychiatric disorders |
| Antidepressant | Bupropion | C13H18ClNO | 239.74 | Feces, Urine | To treat the major depressive disorders |
| Antidepressant | Citalopram | C20H21FN2O | 324.39 | Urine | To treat the major depressive disorders |
| Antidepressant | Escitalopram | C20H21FN2O | 324.39 | Urine | To treat the disturbance of major depression or anxiety |
| Antidepressant | Fluoxetine | C17H18F3NO | 309.33 | Urine | To treat depression, panic disorder, obsessive–compulsive disorder, and bulimia nervosa |
| Antidepressant | Norfluoxetine | C16H16F3NO | 295.299 | Urine, Breast milk | Selective serotonin reuptake inhibitor |
| Antidepressant | Paroxetine | C19H20FNO3 | 329.37 | Urine | To treat depression and disturbance of panic, social anxiety, generalized anxiety, and obsession |
| Antidepressant | Sertraline | C17H17Cl2N | 306.23 | Urine | To treat the disorders of depression, obsession, panic, and social phobia |
| Antidepressant | Reboxetine | C19H23NO3 | 313.39 | Urine | To Treat the disturbance of depression, fear, and attention deficit hyperactivity |
| Antidepressant | Venlafaxine | C17H27NO2 | 277.40 | Urine | To treat the disorder of depression, panic, social anxiety, and generalized anxiety |
| Antidiabetic | Metformin | C4H11N5 | 129.16 | Urine | To control blood glucose |
| Anti-inflammatory analgesic | Acetaminophen | C8H9NO2 | 151.16 | Urine | To relieve pain and fever |
| Anti-inflammatory analgesic | Acetylsalicylic acid | C9H8O4 | 180.16 | Urine | To prevent platelet aggregation, stroke, and myocardial infarction |
| Anti-inflammatory analgesic | Diclofenac | C14H11Cl2NO2 | 296.15 | Bile, Urine | Pain reliever |
| Anti-inflammatory analgesic | Ibuprofen | C13H18O2 | 206.29 | Urine | To treat pain, inflammation, and fever |
| Anti-inflammatory analgesic | Indomethacin | C19H16ClNO4 | 357.79 | Feces, Urine | To mitigate pain, joint stiffness, and swelling |
| Anti-inflammatory analgesic | Ketoprofen | C16H14O3 | 254.28 | Urine | To relieve minor pains like headaches, toothaches, muscle aches, backaches, and menstrual periods |
| Anti-inflammatory analgesic | Naproxen | C14H14O3 | 230.26 | Urine | To relieve pain, fever, inflammatory diseases like rheumatoid arthritis |
| Anti-inflammatory analgesic | Paracetamol | C8H9NO2 | 151.16 | Urine | Painkiller |
| Anti-inflammatory analgesic | Salicylic acid | C7H6O3 | 138.13 | Urine | To treat skin problems like psoriasis and acne |
| Opioid analgesic | Morphine | C17H19NO3 | 285.34 | Feces, Urine | To reduce pain and anxiety and increase happiness |
| Antiseizure | Benzodiazepine | C9H8N2 | 144.17 | Urine | To treat anxiety and seizures |
| Antiseizure | Carbamazepine | C15H12N2O | 236.27 | Urine | To treat epilepsy, neuropathic pain, and bipolar disorder |
| Antiseizure | Ethosuximide | C7H11NO2 | 141.17 | Urine | To treat seizures |
| Antiseizure | Perampanel | C23H15N3O | 349.38 | Feces, Urine | To treat epilepsy and minor seizures |
| Antiseizure | Retigabine | C16H20Cl2FN3O2 | 303.33 | Feces, Urine | To treat partial-onset seizures |
| β-blocker | Metoprolol | C15H25NO3 | 267.36 | Urine | To relax blood vessels, slow heart rate, and decline blood pressure |
| β-blocker | Propranolol | C16H21NO2 | 259.34 | Urine | To treat high blood pressure, slow heart rate, and relieve anxiety signs |
| Hormone | Aldosterone | C21H28O5 | 360.45 | Urine | To treat hypertension and heart failure |
| Hormone (estrogen) | Diethylstilbestrol | C18H20O2 | 268.3 | Bile, Urine | To treat prostate cancer and to prevent premature delivery or miscarriage in women |
| Hormone (estrogen) | Estradiol or 17β-Estradiol | C18H24O2 | 272.38 | Feces, Urine | To treat menopause symptoms like hot flashes, to prevent osteoporosis in menopausal women |
| Hormone (estrogen) | Estriol | C18H24O3 | 288.38 | Urine | To control menopause symptoms like osteoporosis, frequent urinary tract infections, insomnia, vaginal dryness, and hot flashes |
| Hormone (estrogen) | Estrone | C18H22O2 | 270.37 | Urine | To manage symptoms of perimenopausal and postmenopausal |
| Hormone (estrogen) | Ethinylestradiol or 17α-Ethynylestradiol | C20H24O2 | 296.40 | Bile, Feces, Urine | To relieve moderate to severe vasomotor symptoms of menopause, to prevent postmenopausal osteoporosis, to treat moderate acne, and contraceptive side effects |
| Hormone | Levonorgestrel | C21H28O2 | 312.45 | Feces, Urine | To prevent pregnancy |
| Hormone | Progesterone | C21H30O2 | 314.46 | Bile, Urine | To treat abnormal uterine bleeding and intense premenstrual syndrome symptoms |
| Hormone | Testosterone | C19H28O2 | 288.42 | Bile, Urine | To develop the reproductive system in men and organs like prostate and testicles |
| Hormone | Cortisol | C21H30O5 | 362.46 | Urine | To maintain immune function, blood pressure, and anti-inflammatory operations |
| Hormone | Insulin | C257H383N65O77S6 | 5808 | Urine | To control the body's metabolism, provide energy, and diminish blood sugar |
| Hormone | Levothyroxine | C15H11I4NO4 | 776.87 | Feces, Urine | To treat hypothyroidism |
| Hormone | Triiodothyronine | C15H12I3NO4 | 650.98 | Feces, Urine | Affecting on the almost every physiological process in the body |
| Hormone | Somatotropin | C69H114N22O21S2 | 1651.9 | – | To treat short stature and growth failure, and to increase the growth hormone level |
| Lipid regulator | Atorvastatin | C33H35FN2O5 | 558.64 | Bile, Urine | To treat high cholesterol and diminish the risk of heart attack and stroke |
| Lipid regulator | Bezafibrate | C19H20ClNO4 | 361.82 | Urine | To treat hyperlipidemia |
| Lipid regulator | Clofibric acid | C10H11ClO3 | 214.64 | Urine | To treat dyslipidemia |
| Lipid regulator | Gemfibrozil | C15H22O3 | 250.33 | Bile, Urine | To treat dyslipidemia |
| Lipid regulator | Simvastatin | C25H38O5 | 418.57 | Feces, Urine | To treat dyslipidemia |
Toxicological effects of pharmaceuticals and their metabolites in the aquatic environment
| Category | Chemicals | Species | Class | Ecotoxic effects | References |
|---|---|---|---|---|---|
| Antibiotic | Anhydrotetracycline | Algae | Alteration in cell permeability and oxidative stress | (Xu et al. | |
| Antibiotic | Cephalexin | Plant | Decreasing the population | (Liu et al. | |
| Antibiotic | Chlortetracycline | Bacteria | Luminescence inhibition | (Wei et al. | |
| Antibiotic | Ciprofloxacin | Algae | Toxic effects on the antioxidant system | (Nie et al. | |
| Antibiotic | Ciprofloxacin | Fish | Cardiovascular toxicity | (Shen et al. | |
| Antibiotic | Ciprofloxacin | Plant | Decreasing the population | (Liu et al. | |
| Antibiotic | Chlortetracycline | Fish | Growth inhibition | (Liu et al. | |
| Antibiotic | Clarithromycin | Algae | Decreasing the population | (Liu et al. | |
| Antibiotic | Erythromycin | Fish | Inducting the oxidative stress | (Rodrigues et al. | |
| Antibiotic | Erythromycin | Algae | Toxic effects on the antioxidant system | (Nie et al. | |
| Antibiotic | Erythromycin | Fish | Histopathological influences in liver and gills | (Rodrigues et al. | |
| Antibiotic | Erythromycin | Rainbow trout | DNA damage | (Rodrigues et al. | |
| Antibiotic | Erythromycin | Algae | Decreasing the population | (Liu et al. | |
| Antibiotic | Ofloxacin | Algae | Decreasing the population | (Liu et al. | |
| Antibiotic | Oxytetracycline | Fish | Histopathological influences in liver and gills | (Rodrigues et al. | |
| Anticancer | Norfloxacin | Algae | Decreasing the population | (Liu et al. | |
| Antidepressant | Norsertraline | Fish | Bioaccumulation in the liver | (Arnnok et al. | |
| Antiepileptic | Carbamazepine | Crustaceans | Behavioral alterations | (Liu et al. | |
| Antiepileptic | Carbamazepine | Fish | Diminished steroid production | (Fraz et al. | |
| Anti-inflammatory analgesic | Paracetamol | Catfish | Histopathological alterations of the gills and kidneys | (Perussolo et al. | |
| β-blocker | Propanolol | Planktonic crustacean | Decreased heart rate | (Jeong et al. | |
| Hormone | 17α-Ethynylestradiol | – | Fish | Defeminization of female fish | (Aris et al. |
| Lipid regulator | Atorvastatin | Mussel | Metabolic disruption | (Falfushynska et al. | |
| Lipid regulator | Gemfibrozil | Fish | Genetic changes | (Liu et al. | |
| Lipid regulator | Gemfibrozil | Fish | Diminished steroid production | (Fraz et al. |
Fig. 2Molecularly imprinted polymers synthesis including (1) formation of a pre-polymerization complex by self-assembling functional monomers (2) polymerization and crosslinking reactions of the template-monomer complex (3) removal of the template molecules using suitable solvents (A) and main tactics for producing molecularly imprinted polymers based on the nature of interactions between the functional monomers and templates (B)
Common functional monomers, target templates, cross-linkers, and initiators used in molecularly imprinted polymers
| Essential elements | Typical example |
|---|---|
| Functional monomers | |
| Target templates | |
| Cross-linkers | |
| Initiators | 4,4 |
Comparison of polymerization methods for the synthesis of molecularly imprinted polymers
| Method of imprinting | Principle | Advantages | Disadvantages |
|---|---|---|---|
| Bulk polymerization | Functional monomers, templates, initiators, crosslinking agents are uniformly mixed in a certain ratio in a non-polar solvent and sealed in a vacuum for crosslinking polymerization. The resulting bulk polymer is then subjected to crushing and sieving so that the template molecule can be removed from the polymer | Simplicity in synthesis; no requirement for expensive or sophisticated instrumentation; high purity of the produced molecularly imprinted polymers | Low performance; difficulty in template elution; irregular particle in size and shape; time-consuming; fewer binding sites |
| In-situ polymerization | The synthesis of molecularly imprinted polymers is conducted directly in the column by simple polymerization | In-situ preparation, one-step; continuity and uniformity; good porosity; rapid response to the template is assured | Poor selectivity; slow flow rate; short service life; high column pressure; extensive optimization is required for each new template system |
| Precipitation polymerization | The precursors are dissolved in a suitable solvent for reactive polymerization and the Molecularly imprinted polymers precipitate out of the reaction system after the formation of solid microspheres that are insoluble in the reaction medium | Imprinted microspheres with uniform size and large specific surface area; high performance; single preparative step | A large amount of template and solvents; high dilution factor; high requirements for solvent viscosity |
| Suspension polymerization | The reaction precursors, including functional monomers, templates, porogens, cross-linkers, and other substances, dissolved in the selected solvent, followed by the addition of the dispersant. The mixture is further sealed and stirred at high speed | Uniform spherical particles; large scale assembly possible; high reproducibility | Long preparation period; big particle size; specialist surfactant polymers required; poor recognition; the presence of a surfactant and a stabilizer is mandatory |
| Emulsion polymerization | The template, cross-linker, and functional monomer are first emulsified in water, followed by the addition of stabilizers to the disperse phase to eliminate diffusion in the continuous phase | Uniform particle size; the abundance of binding sites on the molecularly imprinted polymer surface | Complex and expensive synthesis; low purity of the products |
| Surface imprinting polymerization | Functional monomers are attached to the surface of the matrix carriers (e. g. SiO2, carbon dots, carbon nanotubes, metal–organic framework) by suitable techniques such as chelation or grafting. Then the template is introduced to the monomer to form a pre-polymerization complex, which is further cross-linked on the matrix carrier surface in the presence of the initiator, forming surface molecularly imprinted polymer | Easy to prepare; large imprinted surface; abundant binding sites; controlled size and shape; good reproducibility; high selectivity and sensitivity | The limited yield on large scale preparation |
| Sol–gel polymerization | Inorganic precursor and template molecules are dissolved in low molecular weight solvent, and the gel is formed by hydrolysis (water) and condensation polymerization | Eco-friendly reaction solvent; good thermal and chemical stability; simple preparation under mild operating conditions; | The difficulty in forming porous silicon; lack of polymerization method and the functional monomer; low sensitivity; the need for high pH hydrolysis |
Fig. 3Formation of hexagonal boron nitride (h-BN)-molecularly imprinted polymers and the solid-phase extraction process. The h-BN was mixed with EGDMA as a crosslinking agent, AIBN as an initiator, methanol as a porogen, and quercetin as a template. Afterward, the product was leached by methanol in a Soxhlet extractor. Reprinted with permission of Springer from ref. (Li and Row 2019). h-BN hexagonal boron nitride; h-BN-MIP hexagonal boron nitride-molecularly imprinted polymer; MIP molecularly imprinted polymer; EGDMA ethylene glycol methacrylate; AIBN 2,2-azobisisobutyronitrile; HPLC high-performance liquid chromatography
Fig. 4Synthesis of peptide imprinted mesoporous silica by 1-dodecyl-3-methylimidazolium chloride amphiphilic ionic liquid as the surfactant through docking oriented imprinting approach. Reprinted with permission of IOP from ref. (Ding et al. 2018)
Fig. 5Routes and fate of discharged pharmaceuticals into the aquatic environment. The pharmaceuticals and their metabolites can infiltrate the aquatic environment. After metabolism in the animal and human body followed by excretion, pharmaceuticals or their metabolites have been significantly discharged as domestic wastewater. They head to wastewater treatment plants and sometimes can transform into more persistent and toxic compounds by additional chemical reactions with the existing substances in wastewaters and the materials used in the wastewater treatment process. The majority of pharmaceuticals are water-soluble with high polarity, therefore they can easily sidestep wastewater treatment plants and enter ground and surface water. WTPs wastewater treatment plants
Application of recent molecularly imprinted polymers in the removal of pharmaceuticals from wastewater
| Pharmaceuticals | Target | Molecularly imprinted polymers | Particle size (nm)/specific surface area (m2 g−1) | Removal method and conditions | Qm or R-MIP | Imprinting factor (IF) b | Synthesis | References |
|---|---|---|---|---|---|---|---|---|
| Antibiotics | Norfloxacin | MIP-MOF/CF | 364/~ 200 | Adsorption: pH = 7 | 456 | 1.93 | Surface imprinting combined with the solvothermal method | (Liu et al. |
| CoFe2O4@TiO2-MMIP | –/88.9 | Adsorption: pH = 6–8 | 14.26 | – | Surface imprinting combined with the solvothermal method | (Fang et al. | ||
| Kitasamycin | MIP | –/– | Adsorption: pH = 8–10 | 127.06 | 2.97 | Surface imprinting | (Chen et al. | |
| Ciprofloxacin | BiPO4@GO-MIP | –/– | Adsorption: pH = 6–8 | 252 | 9.33 | Surface imprinting | (Kumar et al. | |
| Tetracycline | ZnO@NH2-UiO-66 | –/152.99 | Photocatalysis: Visible light 50 W xenon lamp | 61.9% | – | Post-synthetic modification method | (Du et al. | |
| Ag/Ag3VO4/g-C3N4 | –/97.6 | Adsorption: | 16.51 | 1.08 | Surface imprinting and photo-induced polymerization | (Sun et al. | ||
Photocatalysis: | 90.18% | – | ||||||
| Tylosin | MIP | –/– | Adsorption: pH = 8.5 | 74.3 | 1.73 | Precipitation polymerization | (Zeng et al. | |
| Chloramphenicol | Si@MIP-CAP | ~ 439/58.99 | Adsorption: pH = 7 | 32.26 | 2.27 | Precipitation polymerization | (Mohamed Idris et al. | |
| Sulfonamides | MIP | –/144.78 | Adsorption: pH = 7 | 3.33 | 1.44 | Surface polymerization | (Zhu et al. | |
| MIP | –/– | Adsorption: pH = 7 | 12.48 | 1.4 | Prepolymerization | (Fan et al. | ||
| Antiseptics | Triclosan | TCS-CTS-Fe0-MIP | –/– | Adsorption: pH = 6–9 | 20.86 | 1.38 | Surface polymerization | (Chen et al. |
| MIP@Fe3O4 | 200/- | Adsorption: pH = 6–9 | 0.218 | 2.46 | Surface imprinting and sol–gel | (Kong et al. | ||
| Antidepressant | Sertraline | MIP | –/193 | Adsorption: pH = 6–8 | 72.6 | 3.7 | Bulk Polymerization | (Gornik et al. |
| Anticonvulsant | Carbamazepine | Fe3O4@CTS@MIP | 500/265.8 | Adsorption: pH = 9 | 76.34 | 4.83 | Reversible addition-fragmentation chain transfer polymerization | (Wang et al. |
| 4VNIA-MIP | 24.65/384.9 | Adsorption: | 28.40 | 2.72 | Two-step polymerization | (He et al. | ||
Non-steroidal anti-inflammatory drugs | Diclofenac | MIP | –/320 | Adsorption: | 32.5 | – | Bulk polymerization | (Cantarella et al. |
| MIP | 200/– | Adsorption: pH = 7 | 5.5 | – | Precipitation polymerization method | (Amaly et al. | ||
| MIP-TiO2 | > 100/49.07 | Adsorption: pH = 6.5 | 0.16 mg/g | 1.83 | Surface imprinting technology | (Bi et al. | ||
Photocatalysis: | ~ 89% | |||||||
Potassium diclofenac | MIP-BC | –/47.98 | Adsorption: pH = 6 | 1.82 | 5.5 | Bulk polymerization | (Da Silva et al. | |
| MIP-SDS | –/43.36 | 1.12 | 3.2 | |||||
| MIP-TTX-100 | –/42.49 | 0.51 | 1.45 | |||||
| Naproxen | Fe3O4@MIP-ChCl-BuIM | –/– | Adsorption: mg pH = 5 | 90.91 | – | Bulk Polymerization | (Husin et al. | |
| Ketoprofen | MIP | 2–50/209 | Adsorption: pH = 5 | 8.7 | – | Bulk polymerization | (Madikizela et al. | |
| Others | Sildenafil | MOG@HP-MIP | 30 − 100/219.6 | Adsorption: | 17.8 | 2.5 | Surface imprinting technology | (Wan et al. |
| Cyproheptadine | MMIP | 300 ± 20/11.50 | Adsorption: pH = 8 | 48.89 | 4.74 | Surface imprinting technology | (Cao et al. | |
| Amitriptyline | 47.14 | 5.63 | ||||||
| Desloratadine | 47.33 | 5.69 | ||||||
| 8-Chloroazatadine | 46.89 | 6.91 | ||||||
Ketotifen fumarate | 42.14 | 5.68 | ||||||
| 1-Praziquantel enantiomers | MMIPPy | –/– | Adsorption: pH = 6.5 | 1322 | – | Surface imprinting technology | (Do Nascimento et al. | |
| 2-Praziquantel enantiomers | 1508 |
MIM molecularly imprinted materials; MIP molecularly imprinted polymer; MMIP magnetic molecularly imprinted polymer; MIP-MOF/CF molecular imprinting with metal–organic framework particles anchored to porous carbon foam; Si@MIP-CAP silica-grafted molecularly imprinted polymers for chloramphenicol adsorption; TCS triclosan; CTS chitosan; MIP-ChCl-BuIM Molecularly imprinted polymer-choline-imidazole based deep eutectic solvent; MOG@HP-MIP hierarchically porous molecularly imprinted polymers in metal–organic gel; MMIPPy magnetic molecularly imprinted polypyrrole; MIP-BC MIP-SDS MIP-TTX-100 benzalkonium chloride Sodium dodecyl sulfate and Triton ×-100 molecularly imprinted polymers; g-CN graphitic carbon nitrides; NH-UiO-66 Amino-functionalized zirconium-based metal–organic; 4VNIA-MIP 4-Vinyl benzoic acid molecularly imprinted polymers; m adsorbent dosage; t time; V volume; T temperature min minute; h hour
aQm or R–MIP, Maximum adsorption capacity (mg g−1) or removal efficiency of molecularly imprinted polymers (or %)
bIF, Imprinting factor, a ratio between adsorption capacity of molecularly-imprinted and nonimprinted materials
Fig. 6Synthesis process for the MI-MOF/CF composite (A), adsorption isotherms of NOR (B), and adsorption performances of MOF/CF and MI-MOF/CF on NOR, IBU, NAP, SMM, and CAF (C). Reprinted with permission of Elsevier from ref. (Liu et al. 2021d). Ce equilibrium concentration; PF polyurethane foam; CF carbon foam; MI-MOF molecular imprinting metal–organic framework; MI-MOF/CF molecular imprinting metal–organic frameworks/carbon foam; NH-MIL-101 aminated porous chromium-benzenedicarboxylate; NH-MIL-101/CF aminated porous chromium-benzenedicarboxylate/carbon foam; NOR norfloxacin; NAP naproxen; IBU ibuprofen; SMM sulfadimethoxine; CAF caffeine
Fig. 7Synthetic procedure for molecularly imprinted polymer by 1-allyl-3-vinyl imidazolium chloride ionic liquid and 2-acrylamide-2-methyl propane sulfonic acid as a co-functional monomer on the surface of PS-DVB (A), kinetic adsorption curves (B), and adsorption isotherm curves of MIP and NIP towards kitasamycin at 25 ℃ (a), 35 ℃ (b) and 45 ℃ (c), respectively (C). Reprinted with permission of Elsevier from ref. (Chen et al. 2021). MIP molecularly imprinted polymer; PS-DVB poly (styrene–divinylbenzene); NIP non-imprinted polymer; Q adsorption capacity; Ce equilibrium concentration
Fig. 8Synthetic route for MIP@Fe3O4 via sol–gel condensation reaction (A), the binding specificity of MIP@Fe3O4 and NIP@Fe3O4 towards TSC, Ph, and p-CP, (B) and reusability of MIP@Fe3O4 and NIP @Fe3O4 (C). Reprinted with permission of Wiley–VCH from ref. (Kong et al. 2020). MIP molecularly imprinted polymer; NIP non-imprinted polymer; TEOS tetraethylorthosilicate; APTES 3-aminopropyltriethoxysilane; TCS triclosan; Ph phenol; p-CP p-chlorophenol; Q adsorption capacity
Fig. 9Synthetic route for the diclofenac-selective molecularly imprinted polymer (A), the time profile of diclofenac adsorbed by MIP and REF as a reference (B), adsorption performance in 10 min of MIP (C) and REF (D), respectively, towards diclofenac, acetylsalicylic acid, trimethoprim and methyl orange. Reprinted with permission of Elsevier from ref. (Cantarella et al. 2019). MIP molecularly imprinted polymer; REF non-imprinted polymer; DICLO diclofenac; C initial concentration